The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Each year, 500 to 1,000 people in the United States are diagnosed with pulmonary arterial hypertension (PAH). Because this progressive, chronic disorder is rare, it is often under-detected, causing ...

Serge Belanger’s rating is based on a clear path toward FDA approval and the subsequent launch of Yutrepia, a drug developed by Liquidia Technologies for treating pulmonary arterial hypertension (PAH) ...

“One of our organisation’s primary focus areas is pulmonary hypertension, a chronic condition that affects the heart and ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...

Companies that manufacture diagnostics, technology and equipment to address the world’s most pressing medical issues have ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...

CMS has proposed coverage of implantable pulmonary artery pressure sensors for the management of heart failure. Here are five things to know, according to an Oct. 30 memo from CMS: Abbott ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...